Investors & Media

Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study Donidalorsen is one of Ionis’ wholly owned medicines the

Read more
You are now leaving to visit